Peter A. Thompson filed a Form 3 initial statement of beneficial ownership with the SEC on October 29, 2026, reporting indirect holdings of five classes of convertible preferred stock in Aspen Neuroscience, Inc. (NASDAQ:ASPE).

Key Highlights

  • Reporting person: Peter A. Thompson, identified as both a Director and 10% Owner of Aspen Neuroscience, Inc.
  • Series Seed-2 Convertible Preferred Stock: 196,541 underlying shares of Common Stock reported, held indirectly.
  • Series A-1 Convertible Preferred Stock: 642,745 underlying shares of Common Stock reported, held indirectly.
  • Series A-2 Convertible Preferred Stock: 616,984 underlying shares of Common Stock reported, held indirectly.
  • Series B Convertible Preferred Stock: 625,743 underlying shares of Common Stock reported, held indirectly.
  • Series C Convertible Preferred Stock: 507,119 underlying shares of Common Stock reported, held indirectly.
  • Indirect holder: All securities are held by OrbiMed Private Investments VII, LP, according to the filing.

Thompson's Indirect Preferred Stock Holdings Through OrbiMed at Aspen Neuroscience

According to the Form 3 filed on October 29, 2026, Peter A. Thompson holds no directly owned securities in Table I. All reported holdings appear in Table II as derivative securities, specifically five separate series of convertible preferred stock in Aspen Neuroscience, a company focused on neuroscience therapeutics headquartered in San Diego, California. The share counts listed in the filing reflect the number of underlying shares of Common Stock into which each preferred series may convert.

The filing states that pursuant to Aspen Neuroscience's Amended and Restated Certificate of Incorporation, each share of the preferred stock "may be converted, at the option of the holder, at any time." Additionally, the filing discloses that in connection with the completion of the issuer's initial public offering of its Common Stock, each preferred share "will automatically convert on a 1-for-9.8821 basis into shares of Common Stock, for no additional consideration," and that "share numbers give effect to such conversion." The securities are reported to have no expiration date.

All five series of preferred stock are held indirectly through OrbiMed Private Investments VII, LP ("OPI VII"). The filing identifies OrbiMed Capital GP VII LLC as the general partner of OPI VII, and OrbiMed Advisors LLC as the managing member of OrbiMed Capital GP VII LLC. Investment and voting power is exercised through a management committee comprising Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu. Each of those named entities and individuals disclaim beneficial ownership of the shares held by OPI VII, "except to the extent of its or his pecuniary interest therein if any," according to the filing. The form was signed by Jeffrey L. Boerneke as attorney-in-fact under an attached power of attorney.

What Was Disclosed

Peter A. Thompson, a Director and 10% Owner of Aspen Neuroscience, Inc. (NASDAQ:ASPE), filed an initial beneficial ownership statement on October 29, 2026, reporting five series of convertible preferred stock held indirectly through OrbiMed Private Investments VII, LP, with share counts reflecting a 1-for-9.8821 conversion basis into Common Stock.